In preclinical models of KRAS-mutant pancreatic ductal adenocarcinoma, co-inhibition of CDK4/6 and MAPK signaling pathway improved treatment efficacy [27]. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.